Image

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

Recruiting
12-40 years
Female
Phase N/A

Powered by AI

Overview

In this study, researchers want to learn about the connection between heavy bleeding issues and joint hypermobility (loose joints). They want to know if these issues may indicate other connective tissue problems in girls and women with heavy menstrual bleeding who do not have a known cause.

Primary Objective

  • Compare the severity of heavy menstrual bleeding (HMB) in women with and without Generalized joint Hypermobility Syndrome Disorder/hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using bleeding scores.

Secondary Objectives

  • Compare the frequency of co-morbidities in women with and without G-HSD/hEDS.

Description

The researchers will screen for patients referred to St. Jude due to HMB. Patients will be eligible for inclusion and offered to be screened for enrollment in this study if the duration of their menses was greater than or equal to 7 days, and they reported either "flooding" or bleeding through a tampon or napkin in 2 hours or less with most periods, have no identifiable bleeding disorder, and have evidence of severe iron deficiency anemia (hemoglobin < 8 g/dL).

Once enrolled, joint hypermobility will be evaluated using a Beighton score which will be used to assign participants to two groups: with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS). Participants will then undergo a detailed clinical examination to further classify them using the 2017 diagnostic criteria and complete symptom questionnaires. Finally, participants will be consented to TBANK (NCT01354002) and INSIGHT HD (NCT02720679) to provide a sample of leftover blood for banking for future research. Participants will be seen annually for the next 3 years as part of their standard of care to document the course of their symptoms.

Visit 1: Self-BAT Questionnaire, Beighton Score examination, 2017 hEDS examination, PROMIS (Peds/Parent) questionnaire, PHQ15 questionnaire, COMPASS31 questionnaire, Menstrual distress questionnaire (ENDOPAIN), and Heavy menstrual bleeding checklist (both pediatric and adult).

Visit 2: Self-BAT Questionnaire, PROMIS (Peds/Parent) questionnaire, PHQ15 questionnaire, COMPASS31 questionnaire, Menstrual distress questionnaire (ENDOPAIN).

Visit 3: Self-BAT Questionnaire, PROMIS (Peds/Parent) questionnaire, PHQ15 questionnaire, COMPASS31 questionnaire, Menstrual distress questionnaire (ENDOPAIN).

Eligibility

Inclusion Criteria:

  • Female
  • Age 12-40 years
  • Presence of HMB
  • Evidence of severe iron-deficiency anemia (hemoglobin level of < 8 g/dL)

Exclusion Criteria:

  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
  • Current use of anticoagulant and antiplatelet medications
  • Currently pregnant
  • Medical conditions that could cause HMB but are not necessarily a bleeding disorder, including, but not limited to:
    • Uncontrolled hypertension
    • Documented uterine structural abnormality
    • Insulin-dependent diabetes mellitus
    • Chronic kidney disease
    • Chronic liver disease
    • Thyroid disease
    • Documented peripheral arterial disease, venous or arterial vascular events in the past
    • A structural pathology that would explain the HMB
  • Presence of a bleeding disorder indicated by prothrombin time, activated partial

    thromboplastin time, fibrinogen, and von Willebrand factor activity, antigen and factor VIII

  • Persistent thrombocytopenia as defined by a platelet count of <150,000/uL
  • If the participant answers "yes" to any of the following questions, they are
    ineligible
    • Could the patient have a known connective tissue disorder?
    • Family history of sudden death
    • Family history/personal history of uterine rupture or bowel perforation
    • Family history/personal history of arterial rupture
    • Family history/personal history of aneurysm
    • Family history/personal history of an established EDS diagnosis based on genetic evaluation

Study details
    Hypermobile Ehlers-Danlos Syndrome
    Heavy Menstrual Bleeding
    Hypermobility Syndrome (Disorder)

NCT05685199

St. Jude Children's Research Hospital

24 June 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.